Ralf Schmidt
Associate Director, DMPK at Kymera Therapeutics- Claim this Profile
Click to upgrade to our gold package
for the full feature experience.
-
German Native or bilingual proficiency
-
English Native or bilingual proficiency
-
French Limited working proficiency
-
Russian Elementary proficiency
Topline Score
Bio
Marie Roumi PhD
As a senior scientist in DMPK, Ralf was the site Biotransformation Specialist working closely with Medicinal Chemists to provide biotransformation data & expertise into the design process of Hit Identification to Lead Optimization projects. At the Global level, he was a valued member of the AstraZeneca Biotransformation Network and received a CNS/Pain innovative Star Award for the development and application of a novel assay using bi-functional peptide-based trapping agents for the semi-quantitative assessment of reactive metabolite formation. In the year and a half that I have managed Ralf, he constantly worked with a sense of urgency, displayed strong collaborative skills and team spirit while working very independently. Ralf worked meticulously and was always keen to discuss and resolve project related issues. It was a pleasure working with him.
Richard Thompson
I worked with Ralf for over 4 years in his role as biotransformation expert. He was a member of the core team of the cross AstraZeneca scientific network for biotransformation that I led. Ralf has a strong understanding of biotransformation and excellent skills in analytical chemistry. He has a strong drive and was a key contributor in the core team. Some of his major input was in the area of screening for reactive metabolites, where he developed novel methodology. I have always found Ralf to be a great person to work with and would highly recommend him.
Marie Roumi PhD
As a senior scientist in DMPK, Ralf was the site Biotransformation Specialist working closely with Medicinal Chemists to provide biotransformation data & expertise into the design process of Hit Identification to Lead Optimization projects. At the Global level, he was a valued member of the AstraZeneca Biotransformation Network and received a CNS/Pain innovative Star Award for the development and application of a novel assay using bi-functional peptide-based trapping agents for the semi-quantitative assessment of reactive metabolite formation. In the year and a half that I have managed Ralf, he constantly worked with a sense of urgency, displayed strong collaborative skills and team spirit while working very independently. Ralf worked meticulously and was always keen to discuss and resolve project related issues. It was a pleasure working with him.
Richard Thompson
I worked with Ralf for over 4 years in his role as biotransformation expert. He was a member of the core team of the cross AstraZeneca scientific network for biotransformation that I led. Ralf has a strong understanding of biotransformation and excellent skills in analytical chemistry. He has a strong drive and was a key contributor in the core team. Some of his major input was in the area of screening for reactive metabolites, where he developed novel methodology. I have always found Ralf to be a great person to work with and would highly recommend him.
Marie Roumi PhD
As a senior scientist in DMPK, Ralf was the site Biotransformation Specialist working closely with Medicinal Chemists to provide biotransformation data & expertise into the design process of Hit Identification to Lead Optimization projects. At the Global level, he was a valued member of the AstraZeneca Biotransformation Network and received a CNS/Pain innovative Star Award for the development and application of a novel assay using bi-functional peptide-based trapping agents for the semi-quantitative assessment of reactive metabolite formation. In the year and a half that I have managed Ralf, he constantly worked with a sense of urgency, displayed strong collaborative skills and team spirit while working very independently. Ralf worked meticulously and was always keen to discuss and resolve project related issues. It was a pleasure working with him.
Richard Thompson
I worked with Ralf for over 4 years in his role as biotransformation expert. He was a member of the core team of the cross AstraZeneca scientific network for biotransformation that I led. Ralf has a strong understanding of biotransformation and excellent skills in analytical chemistry. He has a strong drive and was a key contributor in the core team. Some of his major input was in the area of screening for reactive metabolites, where he developed novel methodology. I have always found Ralf to be a great person to work with and would highly recommend him.
Marie Roumi PhD
As a senior scientist in DMPK, Ralf was the site Biotransformation Specialist working closely with Medicinal Chemists to provide biotransformation data & expertise into the design process of Hit Identification to Lead Optimization projects. At the Global level, he was a valued member of the AstraZeneca Biotransformation Network and received a CNS/Pain innovative Star Award for the development and application of a novel assay using bi-functional peptide-based trapping agents for the semi-quantitative assessment of reactive metabolite formation. In the year and a half that I have managed Ralf, he constantly worked with a sense of urgency, displayed strong collaborative skills and team spirit while working very independently. Ralf worked meticulously and was always keen to discuss and resolve project related issues. It was a pleasure working with him.
Richard Thompson
I worked with Ralf for over 4 years in his role as biotransformation expert. He was a member of the core team of the cross AstraZeneca scientific network for biotransformation that I led. Ralf has a strong understanding of biotransformation and excellent skills in analytical chemistry. He has a strong drive and was a key contributor in the core team. Some of his major input was in the area of screening for reactive metabolites, where he developed novel methodology. I have always found Ralf to be a great person to work with and would highly recommend him.
Experience
-
Kymera Therapeutics
-
United States
-
Biotechnology Research
-
100 - 200 Employee
-
Associate Director, DMPK
-
Apr 2023 - Present
-
-
-
EMD Serono, Inc.
-
Pharmaceutical Manufacturing
-
700 & Above Employee
-
Principal Scientist, DMPK NCE Project Representative
-
May 2013 - Apr 2023
Responsible for providing discovery NCE DMPK support from early inception through late-stage development for Immunology, Oncology, and Immuno-Oncology projects Responsible for interfacing with cross-disciplinary project teams and to provide scientific support in addressing and solving ADME concerns Prepared pharmacokinetic sections of regulatory documents (e.g. IB, IMPD, IND) and provided appropriate support for interactions with Health Authorities (EMA, FDA, PMDA) Propose and implement internal strategies to address in vitro/in vivo regulatory DMPK concerns Show less
-
-
-
AstraZeneca
-
United Kingdom
-
Pharmaceutical Manufacturing
-
700 & Above Employee
-
Principal Scientist
-
Apr 1999 - Jun 2012
DMPK (2006-2012): drug metabolism, bioanalysis, MetID and biotransformation studies in vitro and in vivo, MetID and assay development for quantification of reactive metabolites, synthesis and scale up of metabolites using enzymatic systems for structural elucidation by NMR, coaching and advising MedChem drug design teams in Hit-to-Lead and Lead optimization discovery projects, core team member AZ Global Biotransformation network Analytical chemistry: LC-MS/MS, HPLC, counter-ion analysis, capillary electrophoresis MedChem (1999-2005): peptide synthesis, SAR studies of GPCR ligands for target validation, development of metabolically stable peptides for target validation in vitro and in vivo studies, support of in vitro screening assay development in pharmacology, synthesis of fluorescence-labeled peptide ligands for pharmacology assays and histochemistry Show less
-
-
-
Astra Research Centre Montreal
-
Montreal, Canada Area
-
Senior Scientist
-
Aug 1994 - Apr 1999
- Established peptide synthesis and analytical chemistry capabilities at Astra in Montreal - Supplied all projects of the Global GPCR initiative with natural peptide ligands, designed and synthesized metabolically stabilized peptide analogs and peptidomimetics for in vitro and in vivo target validation within the pharmacology - Supported peptide-related activities company-wide - Established peptide synthesis and analytical chemistry capabilities at Astra in Montreal - Supplied all projects of the Global GPCR initiative with natural peptide ligands, designed and synthesized metabolically stabilized peptide analogs and peptidomimetics for in vitro and in vivo target validation within the pharmacology - Supported peptide-related activities company-wide
-
-
-
Institut de recherches cliniques de Montréal (IRCM) / Montreal Clinical Research Institute
-
Canada
-
Research Services
-
200 - 300 Employee
-
Post-doc
-
Nov 1991 - Jul 1994
peptide synthesis, conformationally constraint peptidomimetics, opioid peptide pharmacology, GPCR peptide synthesis, conformationally constraint peptidomimetics, opioid peptide pharmacology, GPCR
-
-
-
-
Laboratory Head Peptide Research
-
Jun 1989 - Nov 1991
established peptide synthesis lab, built and led peptide research group within the neurochemistry department established peptide synthesis lab, built and led peptide research group within the neurochemistry department
-
-
-
The Martin Luther University of Halle-Wittenberg
-
Germany
-
Higher Education
-
400 - 500 Employee
-
Research Assistant
-
Sep 1985 - May 1989
- Peptide synthesis and analysis - teaching undergraduate course in organic synthesis and natural product chemistry - Peptide synthesis and analysis - teaching undergraduate course in organic synthesis and natural product chemistry
-
-
Education
-
1991 - 1994
Clinical Research Institute Montreal (IRCM)
Post-doc, Peptide synthesis & pharmacology -
Martin-Luther-Universität Halle-Wittenberg
Doctor of Philosophy (PhD), Biochemistry, Peptide Chemistry -
The Martin Luther University of Halle-Wittenberg
Master of Science (MSc), Biochemistry
Community
